Iasibon

Ibandronic Acid, the active ingredient in Iasibon, is a bisphosphonate presented as an injection for intravenous use. It treats osteoporosis and Paget's disease of bone in adults at risk of fractures.

GNH USA supplies Iasibon as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iasibon is a bisphosphonate indicated for conditions involving excessive bone resorption.

Osteoporosis: reduces the risk of vertebral and non‑vertebral fractures in postmenopausal women and men at high fracture risk. Paget's disease of bone: normalizes bone turnover and alleviates bone pain associated with the disorder.

Iasibon may cause a range of adverse reactions.

Common Side Effects: - Acute phase reaction (fever, muscle aches) - Nausea or vomiting - Headache - Injection site pain

Serious or Rare Side Effects: - Osteonecrosis of the jaw - Atypical femoral fracture - Severe renal impairment

Before using Iasibon, consider the following safety measures.

Renal function assessment: evaluate baseline creatinine clearance prior to infusion. Calcium and vitamin D status: ensure adequate levels to reduce hypocalcemia risk. Concurrent bisphosphonate therapy: avoid overlapping treatment with other bisphosphonates. Pregnancy and lactation: use only if clearly needed; risk to fetus or infant is unknown. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iasibon can interact with several medicines; monitor accordingly.

Major Interactions (Avoid): - Concurrent use with other bisphosphonates: increased renal toxicity risk. - Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): may exacerbate renal impairment. - Hypocalcemic agents without calcium supplementation: can worsen hypocalcemia.

Moderate Interactions (Monitor Closely): - Calcium supplements taken within 30 minutes of infusion: may reduce drug absorption; separate dosing. - Vitamin D analogues: monitor serum calcium levels. - Corticosteroids: may diminish bone‑protective effect; monitor bone density.